Treatment patterns and clinical outcomes of Recombinant Follicle Stimulating Hormone in South Korean patients who received Controlled Ovarian Hyper-stimulation: Results from a retrospective observational chart review study

Ferring pharmaceuticals Korea0 个研究点目标入组 700 人开始时间: 待定最近更新: 2020年1月14日

试验速览

暂无简介。

•1. South Korean female patients who received controlled ovarian hyperstimulation for assisted reproductive technology procedures such as IVF or ICSI from January 2013 to December 2017.
•2. Women between the ages of 18 and 40 years at the time of controlled ovarian hyperstimulation.
•3. The first controlled ovarian hyperstimulation cycle.
•4. Body mass index between 17.5 and 32.0 kg/m2 (both inclusive).
•5. Subjects who received the procedure using a GnRH antagonist cycle.
•6. Subjects who received rFSH only.
•7. Controlled ovarian hyperstimulation cycle = 20 days.
•8. Regular menstrual cycles of 24–35 days (both inclusive), presumed to be ovulatory.
•9. AMH levels available within 1 year prior to controlled ovarian hyperstimulation.

•1. Known endometriosis stage III–IV.
•2. Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy and before week 24 of pregnancy).
•3. Any known clinically significant systemic disease (e.g., insulin-dependent diabetes).
•4. Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
•5. Any known endocrine or metabolic abnormalities.
•6. Known moderate or severe impairment of renal or hepatic function.
•7. Use of any rFSH preparations during the last 3 months before controlled ovarian hyperstimulation.

发起方

Ferring pharmaceuticals Korea